$CRMD News
Last published 2d ago
- 2d agoHRTXCRMDCorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of CareGlobeNewswireAdds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform
- 2d agoCRMDHRTXCorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of CareGlobeNewswireAdds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash,
- 5d agoCRMDCorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026GlobeNewswirePARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for...
- 5d agoCRMDCorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026GlobeNewswirePARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens
- 1w agoCRMDCorMedix Inc. - PRESS RELEASE DATED NOVEMBER 2, 2026Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoCRMDCorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash PositionGlobeNewswirePARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the
- 3w agoCRMDCormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal DiseasesGlobeNewswirePARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application
- 3w agoATNMCRMDOVIDActinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerPR NewswireNEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment
- 2mo agoCRMDWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - CORMEDIX INCEarnings Call TranscriptsGood afternoon, everyone. I'm Rahul Sood, Managing Director in the Healthcare Investment Banking Group at Wells Fargo. I'm joined on the stage today with Joe Tedisco, Chairman and CEO of CoreMedix. Joe, welcome. Thank yo
- 2mo agoCRMDCorMedix Therapeutics to Participate in the Wells Fargo Healthcare ConferenceGlobeNewswirePARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 3mo agoCRMDXHGIVDADFSCToday's Stocks in the NewsGlobeNewswireDENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts. CorMedix
- 3mo agoCRMDCormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call
- 3mo agoCRMDCorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026GlobeNewswirePARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on
- 5mo agoCRMDU.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent LitigationGlobeNewswirePARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District
- 6mo agoCRMDCormedix Therapeutics to Participate in two Upcoming Investor ConferencesGlobeNewswirePARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets
- 6mo agoCRMDCormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today
- 6mo agoCRMDCorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026GlobeNewswirePARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on
- 6mo agoCRMDCorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation PatientsGlobeNewswire– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related discontinuations and drug-drug
- 7mo agoCRMDCorMedix to Participate in Needham Virtual Healthcare ConferenceGlobeNewswirePARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 8mo agoCRMDCorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at
- 8mo agoCRMDCorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026GlobeNewswireBERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases
- 9mo agoCRMDCorMedix to Participate in Upcoming Investor ConferencesGlobeNewswireBERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases
- 9mo agoCRMDCorMedix Therapeutics Announces Share Repurchase ProgramGlobeNewswireBERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases
- 9mo agoCRMDCorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026GlobeNewswireBERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases
- 10mo agoCRMDCorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases
- 10mo agoCRMDCorMedix Therapeutics Announces Leadership and Board UpdatesGlobeNewswireBERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases
- 10mo agoCRMDCorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business UpdatesGlobeNewswire‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million and $81 million ‒ ‒
- 10mo agoCRMDCorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCathGlobeNewswireBERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases
- 12mo agoTLPHCRMDTalphera Announces Third Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 12mo agoCRMDHUMAKBLBSLRXStrong Earnings and Biotech Resilience Define the Midweek MomentumGlobeNewswireDENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB:KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research
- 12mo agoCRMDCorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 GuidanceGlobeNewswire‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a
- 1y agoCRMDCorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025GlobeNewswireBERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 1y agoCRMDCorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCathGlobeNewswireBERKELEY HEIGHTS, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 1y agoTLPHCRMDTalphera Announces the Appointment of Joe Todisco to Board of DirectorsPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoCRMDCorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue GuidanceGlobeNewswire‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ‒ ‒ Q3 2025 Unaudited DefenCath Net Revenue of more than $85 million ‒ ‒ Raising FY 2025 Pro Forma Net Revenue Guidance to at least $375 million ‒ ‒
- 1y agoCRMDCorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYOGlobeNewswire- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant - - Topline Results from ReSPECT Study Expected in 2Q 2026 -
- 1y agoCRMDCorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoCRMDTLPHCorMedix Announces Strategic Minority Investment in TalpheraGlobeNewswireBERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
- 1y agoTLPHCRMDTalphera Announces Private Placement Financing of up to $29 Million Priced At-the MarketPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoCRMDCorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership TeamGlobeNewswire- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -
- 1y agoCRMDCorMedix to Participate in Upcoming Investor ConferencesGlobeNewswireBERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
- 1y agoCRMDCorMedix, Inc. (CRMD) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCRMDCormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒
- 1y agoCRMDCorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care SettingsGlobeNewswireTransformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth
- 1y agoCRMDCorMedix Inc. Announces Pricing of Public Offering of Common StockGlobeNewswireBERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 1y agoCRMDCorMedix Inc. Announces Proposed Public Offering of Common StockGlobeNewswireBERKELEY HEIGHTS, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 1y agoCRMDCorMedix inc. Announces Customer ImplementationGlobeNewswireBERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 1y agoCRMDCorMedix Inc. To Participate In The Jefferies Global Healthcare ConferenceGlobeNewswireBERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 1y agoCRMDCorMedix Inc. to Participate in the RBC Global Healthcare ConferenceGlobeNewswireBERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 1y agoCRMDCorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) --